Posts

Clinical Insights: March 20, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Lenmeldy™ (atidarsagene autotemcel) – New Drug Approval – March 18, 2024 – Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies…

Read More...

Exploring Legislative Updates on Our Latest Podcast Episode

In our latest 340B Insider Podcast episode, we’re thrilled to have Ted Slafsky, Publisher and CEO of the 340B Report and Founder & Principal of Wexford Solutions LLC, join us. Ted dives into ongoing court decisions, state-level progress, the draft “Sustain 340B Act,” and shares insightful perspectives on potential implications of changes in Senate leadership…

Read More...

Clinical Insights: March 6, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Letybo® (letibotulinumtoxinA-wlbg) Powder for Injection – New Drug Approval – February 29, 2024 – Hugel, a global total medical aesthetics company, announced that the company has received marketing approval…

Read More...

Clinical Insights: February 29, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Amtagvi™ (lifileucel) Suspension for Intravenous Infusion –New Orphan Drug Approval  –February 16, 2024 – The U.S. Food and Drug Administration approved Amtagvi™ (lifileucel), the first cellular therapy indicated for the…

Read More...

Clinical Insights: February 14, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Eohilia™ (budesonide) Oral Suspension – New Drug Approval – February 9, 2024 – Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) has approved Eohilia™ (budesonide oral suspension),…

Read More...

Clinical Insights: February 7, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Yescarta® (axicabtagene ciloleucel) Suspension for Intravenous Infusion – New Label Expansion – January 30, 2024 – Kite, a Gilead Company (Nasdaq: GILD), announced…

Read More...

Clinical Insights: January 24, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Balversa® (erdafitinib) Tablets – New Label Expansion – January 19, 2024 – The Food and Drug Administration approved erdafitinib (Balversa®, Janssen Biotech) for adult patients with locally advanced or metastatic…

Read More...

Connect with RxStrategies at 340B Coalition Winter Conference

The RxStrategies team is thrilled to be attending the upcoming 2024 340B Coalition Winter Conference in San Diego, from January 29th to 31st. We could not agree more that the importance of 340B to the patient care mission has never been greater. We look forward to coming together with other members of the 340B community…

Read More...

Clinical Insights: January 10, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Zelsuvmi™ (berdazimer sodium) Topical Gel – New Drug Approval – January 5, 2024 – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the U.S. Food and Drug Administration (FDA) has approved…

Read More...

Clinical Insights: January 3, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Wainua™ (eplontersen) Injection – New Orphan Drug Approval – December 21, 2023 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has approved…

Read More...

Clinical Insights: December 20, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Welireg™ (belzutifan) – New Drug Approval – December 14, 2023 – The Food and Drug Administration approved belzutifan (Welireg™, Merck & Co., Inc.) for patients with advanced renal cell carcinoma…

Read More...

Clinical Insights: December 13, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Casgevy™ (exagamglogene autotemcel) – New Drug Approval – December 8, 2023 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced that the U.S. Food and Drug Administration…

Read More...